Adipose tissue-derived stem cells show considerable promise for regenerative medicine applications

Harasymiak-Krzyżanowska, Izabela; Niedojadło, Alicja; Karwat, Jolanta; Kotuła, Lidia; Gil-Kulik, Paulina; Sawiuk, Magdalena; Kocki, Janusz

doi:10.2478/s11658-013-0101-4

Cited by 68 publications

(57 citation statements)

References 31 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The isolated stem cells are easily grown in culture, and they preserve their properties over many passages. These advantages make adipose tissue an attractive alternative source of stem cells [2, 3, 5, 15, 16]. …”

Section: Discussionmentioning

confidence: 99%

“…This allows autologous, as well as allogeneic, transplantation of MSCs. In addition, there is no reported teratoma formation, and there are no moral objections or ethical controversies involved in their application [15, 16]. These advantageous properties lead to the idea of experimental and clinical applications of MSCs to treat different human diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study

et al. 2016

View full text Add to dashboard Cite

BackgroundThis prospective clinical case series aimed to investigate the safety of subretinal adipose tissue-derived mesenchymal stem cell (ADMSC) implantation in advanced stage retinitis pigmentosa (RP).MethodsThis study included 11 patients with end-stage RP who received subretinal implantation of ADMSCs. All patients had a total visual field defect and five of them only had light perception. The best corrected visual acuity (BCVA) in the study was 20/2000. All patients had undetectable electroretinography (ERG). The worst eye of the patient was operated on and, after total vitrectomy with a 23 gauge, ADMSCs were injected subretinally. Patients were evaluated at day 1, at weeks 1–4, and then once a month for 6 months, postoperatively. BCVA, anterior segment and fundus examination, color photography, and optical coherence tomography (OCT) were carried out at each visit. Fundus fluorescein angiography (FFA), perimetry, and ERG recordings were performed before treatment and at the end of month 6, and anytime if necessary during the follow-up.ResultsAll 11 patients completed the 6-month follow-up. None of them had systemic complications. Five patients had no ocular complications. One of the patients experienced choroidal neovascular membrane (CNM) at the implantation site and received an intravitreal anti-vascular endothelial growth factor drug once. Five patients had epiretinal membrane around the transplantation area and at the periphery, and received a second vitrectomy and silicon oil injection. There was no statistically significant difference in BCVA and ERG recordings from baseline. Only one patient experienced an improvement in visual acuity (from 20/2000 to 20/200), visual field, and ERG. Three patients mentioned that the light and some colors were brighter than before and there was a slight improvement in BCVA. The remaining seven patients had no BCVA improvement (five of them only had light perception before surgery).ConclusionsStem cell treatment with subretinal implantation of ADMSCs seems to have some ocular complications and should be applied with caution. The results of this study provide the first evidence of the short-term safety of ADMSCs in humans, and clarifies the complications of the therapy which would be beneficial for future studies. To optimize the cell delivery technique and to evaluate the effects of this therapy on visual acuity and the quality of life of these patients, future studies with a larger number of cases will be necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Bununla birlikte belli bazı hastalıkların tedavisi için klinik çalımalar halen devam etmektedir. [25] MEZENK‹MAL KÖK HÜCRELER ‹LE ‹LG‹L‹ GÜNCEL KL‹N‹K UYGULAMALAR…”

Section: Self-renewal (Kendini Yenileyebilme)unclassified

Stem cells; mesenchymal stem cells and current clinical applications

Tekeli¹

2016

FNG & Bilim Tıp Transplantasyon Dergisi

View full text Add to dashboard Cite

Stem cells are defined as a type of cell that have the features of self-renewal, unlimited proliferation capacity, potential of differentiation into other cell types and ability to repair damaged structure when given to damaged tissue. Stem cells are preferred for regenerative medical applications because of their abundance, being easily obtained, ability to proliferate by differentiating into many cell types and being transplantable safely and effectively to recipients. In this review, we introduce mesenchymal stem cells as one of the most important sources of stem cells that have clinical applications and give examples of their usage areas in the clinic and of studies.Keywords: Clinical application; mesenchymal stem cells; stem cell. Stem cells; mesenchymal stem cells and current clinical applications ÖZKök hücreler; kendilerini yenileyebilme, sınırsız çoğalabilme, kendilerinden başka hücrelere farklılaşabilme, hasarlı dokuya verildiğinde hasarlı yapıyı onarabilme özellikleri ile tanımlanan hücre tipidir. Kök hücreler bol miktarda bulunmaları, kolay elde edilebilmeleri, birçok hücre tipine farklılaşarak çoğalabilmeleri, alıcılara güvenli ve etkin bir şekilde nakledilebilmeleri nedeniyle rejeneratif tıp uygulamalarında tercih edilmektedir. Bu derlemede, klinikte uygulamaları bulunan ve en önemli kök hücre kaynaklarından biri olan mezenkimal kök hücreler tanıtılacak, klinikteki kullanım alanları ve çalışmalardan örnekler verilecektir.

show abstract

“…It is essential to find renewable islet replacement tissue sources that do not elicit ethical concerns that impede their clinical application. Postnatal-derived mesenchymal stem cells (MSCs), such as those from adipose tissue, present fewer ethical concerns and are considered possible sources of transplantable insulin-producing cells [5,6,9,11,12]. Due to its plasticity and easy availability, placental tissue is very promising in regenerative medicine.…”

Section: Introductionmentioning

confidence: 99%

miR-375 induces human decidua basalis-derived stromal cells to become insulin-producing cells

Shaer¹,

Azarpira²,

Vahdati³

et al. 2014

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

This paper focuses on the development of renewable sources of isletreplacement tissue for the treatment of type I diabetes mellitus. Placental tissue-derived mesenchymal stem cells (MSCs) are a promising source for regenerative medicine due to their plasticity and easy availability. They have the potential to differentiate into insulin-producing cells. miR-375 is a micro RNA that is expressed in the pancreas and involved in islet development. Human placental decidua basalis MSCs (PDB-MSCs) were cultured from full-term human placenta. The immunophenotype of the isolated cells was checked for CD90, CD105, CD44, CD133 and CD34 markers. The MSCs (P3) were chemically transfected with hsa-miR-375. Total RNA was extracted 4 and 6 days after transfection. The expressions of insulin, NGN3, GLUT2, PAX4, PAX6, KIR6.2, NKX6.1, PDX1, and glucagon genes were evaluated using real-time qPCR. On day 6, we tested the potency of the clusters in response to the high glucose challenge and assessed the presence of insulin and NGN3 proteins via immunocytochemistry. Flow cytometry analysis confirmed that more than 90% of the cells were positive for CD90, CD105 and CD44 and negative for CD133 and CD34. Morphological changes were followed from day 2. Cell clusters formed during day 6. Insulin-producing clusters showed a deep red color with DTZ. The expression of pancreatic-specific transcription factors increased remarkably during the four days after transfection and significantly increased on day 7. The clusters were positive for insulin and NGN3 proteins, and C-peptide and insulin secretion increased in response to changes in the glucose concentration (2.8 mM and 16.7 mM). In conclusion, the MSCs could be programmed into functional insulin-producing cells by transfection of miR-375.

show abstract

Adipose tissue-derived stem cells show considerable promise for regenerative medicine applications

Cited by 68 publications

References 31 publications

Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study

Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study

Stem cells; mesenchymal stem cells and current clinical applications

miR-375 induces human decidua basalis-derived stromal cells to become insulin-producing cells

Contact Info

Product

Resources

About